Avalon Pharmaceuticals Sets Second Quarter 2008 Conference Call Date
05 Agosto 2008 - 10:00AM
Business Wire
Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced that it
is scheduled to release financial results for the second quarter of
2008 on Wednesday, August 13, 2008, at approximately 10:00 am
Eastern Time. The Company will host a conference call later that
day at 1:00 pm Eastern Time to provide a company update and discuss
the financial results for the quarter. Interested investors,
analysts, members of the media and the general public can listen to
the call live over the Internet or by dialing the numbers listed
below. Conference Call details: Dial-In: � (877) 548-7913 (U.S.)
(719) 325-4932 (International) Passcode: 3593548 � Webcast: To
access the call by live webcast, please visit the Investor
Relations section of our website at http://www.Avalonrx.com. An
archived version of the webcast will be available for seven (7)
days on the Company's website. About Avalon Pharmaceuticals Avalon
is a biopharmaceutical company focused on the discovery,
development and commercialization of first-in-class cancer
therapeutics. Avalon�s lead product candidate, AVN944,�an IMPDH
inhibitor, is in Phase II clinical development. Avalon also has
preclinical programs to develop inhibitors of the Beta-catenin and
Aurora/Centrosome pathways,�discovery programs�for�inhibitors
of�the Survivin�and Myc�pathways and partnerships with Merck,
AstraZeneca/MedImmune, ChemDiv, Medarex, and Novartis. AvalonRx� is
the company�s proprietary platform�which is based
on�large-scale�biomarker identification and monitoring, used to
discover and develop therapeutics for pathways that have
historically been characterized as "undruggable." Avalon is
headquartered in Germantown, MD.
Avalon (NASDAQ:AVRX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Avalon (NASDAQ:AVRX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Avalon Pharmaceuticals (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Avalon Pharmaceuticals, Inc.